Competitive Intelligence
2 projects tracked · latest scans below
danbury
Heme-Onc Competitive Landscape (PCNSL / PV / TCL / GvHD)
June 4, 2026
Lacutamab's TELLOMAK Phase 2 PTCL trial closed enrollment as of 2026-06-02, signaling an imminent readout for Innate Pharma's KIR3DL2 program in nodal T-cell lymphoma.
View report →
painswick
Obesity and Type 2 Diabetes
June 4, 2026
Eli Lilly executed a coordinated Phase 3 site expansion across its full eloralintide and orforglipron complication-specific program today, while two Novo Nordisk early-pipeline molecules (NNC0113-5840, NNC0497-0040) both opened recruitment in Phase 1.
View report →
Generated by Claude Code + ClinicalTrials.gov MCP ·
clinicaltrials.gov
Rendered: 2026-06-05T02:14:25.651Z